

Supplementary table 1: MCMC parameter estimate results (mean estimate, HDI5, HDI95, $R_{\hat{}}$) for antibiotics, HCT phases and growth rates (intercepts) from 3 independent MCMC runs with 10,000 samples each.

	mean estimate	5% of all MCMC samples less than	95% of all MCMC samples less than	Gelman-Rubin statistic ($R_{\hat{}}$)
Growth rate	0.709	-0.128	1.555	1.001
Phase I	-0.627	-1.851	0.606	1.000
Phase II	-0.765	-1.683	0.119	1.000
piperacillin tazobactam	-0.928	-1.739	-0.073	1.000
meropenem	-1.015	-2.307	0.407	1.000
metronidazole	-0.505	-2.245	1.215	1.000
cephalosporins (gen. 1-3)	-0.850	-2.748	0.942	1.000
vancomycin (PO)	-0.352	-2.010	1.238	1.000
cefepime	-0.236	-1.852	1.437	1.000
linezolid	0.642	-3.843	4.847	1.000
fluoroquinolones	-0.081	-0.764	0.575	1.000
vancomycin	-0.242	-1.025	0.372	1.001
trimethoprim-sulfamethoxazole	-0.035	-0.864	0.817	1.000
atovaquone	0.383	-0.732	1.651	1.001